The trial focuses on adults who have obesity together with type 2 diabetes. The experimental medicine being tested is MET097, which is administered as a subcutaneous injection once each week, and it is compared with a matching placebo. Participants will be randomly placed into one of the two groups, and both groups will receive weekly injections for the duration of the study.
The purpose of the study is to see if MET097 helps participants lose more weight than the placebo after about 64 weeks. Throughout the trial, participants will visit the clinic regularly for weight checks, safety assessments, and blood tests, including a measurement of HbA1c, a test that shows the average blood‑sugar level over the past two to three months. Additional evaluations will monitor changes in cholesterol, blood pressure, and overall health status, and the study will continue with follow‑up visits for up to roughly 84 weeks.
1enrollment
after joining the study, a consent form is completed and basic health information is recorded.
the information is reviewed to confirm eligibility for the trial.
2baseline assessment
a baseline visit is scheduled within the first two weeks of enrollment.
during this visit, weight, blood pressure, blood samples for hbA1c and other laboratory tests, and a health questionnaire are collected.
the results create a reference point for all future measurements.
3randomization
after the baseline assessment, you are randomly assigned to receive either met097 or a placebo injection.
the assignment is unknown to you and the study staff who interact with you.
4start of weekly injections
the first injection is administered at the baseline visit.
the injection is a subcutaneous (under the skin) dose of met097 solution for injection, 5 mg/mL, given once each week.
if assigned to the placebo group, an inactive injection of the same appearance is given on the same schedule.
5regular follow‑up visits
clinic visits occur at regular intervals (for example, weeks 4, 12, 24, 36, 64, and 84).
at each visit, weight, blood pressure, and a short health questionnaire are recorded.
blood samples are taken to measure hbA1c, fasting triglycerides, non‑hdl‑c, and other safety labs.
any side effects or concerns are reviewed and documented.
6primary efficacy evaluation
at week 64, the primary outcome (percent change in body weight from baseline) is calculated.
additional measurements of weight, hbA1c, blood pressure, and laboratory values are compared with baseline values.
7extended treatment period
after the week‑64 evaluation, weekly injections continue for an additional 20 weeks, ending at week 84.
follow‑up visits continue as described in step 5.
8final assessment and study completion
at week 84, final measurements of weight, hbA1c, blood pressure, and laboratory tests are performed.
the study medication is discontinued after the final dose.
all collected data are used for the final analysis of safety and efficacy.
Who Can Join the Study?
Provide a signed and dated informed consent form, showing you agree to join the study.
Be an adult (male or female) who is 18 years old or older.
Have a BMI of 27 or higher at the screening visit. BMI (body mass index) is a number that compares your weight to your height.
Have type 2 diabetes (high blood sugar) for at least 6 months before the screening, based on your own report or medical records.
Show a HbA1c test result between 6.5% and 10.0% at screening and have been on a stable diabetes treatment for at least 90 days. HbA1c measures your average blood sugar level over the past 2–3 months.
Be treated for diabetes with diet and exercise alone or with oral medicines, but not with DPP-4 inhibitors (a class of pills that lower blood sugar). You must NOT be taking GLP-1 agonists (injection medicines that lower blood sugar) or insulin (a hormone given by injection to control blood sugar).
Be motivated, able, and willing to self‑inject the study drug (or have a trained family member or caregiver give the injection if you have vision or physical difficulties), check your blood sugar by a finger‑stick test (including a weekly fasting glucose measurement), follow the lifestyle advice (such as diet and exercise plans), and complete the required paperwork and questionnaires.
Who Cannot Join the Study?
Being a female who is breastfeeding or pregnant at the time of screening or becomes pregnant before the study starts.
Being unwilling or unable to follow the required birth‑control (contraceptive) rules.
Having Type 1 diabetes or any other form of diabetes besides Type 2 diabetes.
Having had diabetic ketoacidosis (a serious condition where the body makes too many acids) or a hyperosmolar state (a very high‑blood‑sugar emergency) within the past year.
Having experienced severe low blood sugar (hypoglycemia) or not feeling the warning signs of low blood sugar in the past six months.
Having a kidney‑function test called estimated glomerular filtration rate (eGFR) that is lower than 30 mL/min/1.73 m² (this test measures how well the kidneys filter waste).
Having a blood test for thyroid‑stimulating hormone (TSH) that is below 0.4 or above 6.0 (TSH checks how well the thyroid gland is working). Participants on stable thyroid medicine may be allowed.
Having very high blood pressure at screening, defined as a seated systolic pressure of 180 mm Hg or higher, or a diastolic pressure of 120 mm Hg or higher.
Want to learn more about this study or check if you can participate? Contact us.
Trial status
Country
Status
Recruitment Start
Bulgaria
Recruiting
15.05.2026
Czechia
Recruiting
15.05.2026
Germany
Recruiting
15.05.2026
Hungary
Not recruiting
15.05.2026
Poland
Recruiting
15.05.2026
Romania
Recruiting
15.05.2026
Slovakia
Recruiting
15.05.2026
Spain
Recruiting
15.05.2026
Trial locations
MET097 is an experimental injectable medicine that works by activating the GLP‑1 receptor in the body. It is designed to stay active for a long time, so it can be given once a week under the skin. In this study, the drug is being tested to see if it can help people who have overweight or obesity together with type‑2 diabetes lose weight and improve their blood sugar control.
Obesity – Obesity is a condition where a person carries an excess amount of body fat. It usually develops over time as calorie intake consistently exceeds energy use. As weight increases, the body may become less able to move easily and may feel more tired during daily activities. The accumulation of fat often spreads to different parts of the body, making clothing feel tighter and affecting physical comfort. Continued weight gain can further reduce mobility and increase strain on joints.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Bulgaria 
Czechia 
Germany 
Hungary 
Poland 
Romania 
Slovakia 
Spain 
